Abstracts tagged "dermatomyositis"

Abstract Number: 296 • 2015 ACR/ARHP Annual Meeting
Different Patterns of Involvement of Thigh Muscles in Dermatomyositis and Polymyositis Using Fat-Suppressed Magnetic Resonance Sequences
Nicolo Pipitone¹, Antonella Notarnicola², Lucia Spaggiari³, Gabriele Levrini⁴, Arnaldo Scardapane⁵, Florenzo Iannone⁶, Giovanni Lapadula⁶, Giulio Zuccoli⁷ and Carlo Salvarani⁸, ¹Unità di Reumatologia, Reggio Emilia, Arcispedale Santa Maria Nuova, Bari, Italy, ²Karolinska Hospital, Rheumatology Unit, Stockholm, Sweden, ³Radiology, Arcispedale S Maria Nuova, Reggio Emilia, Italy, ⁴Arcispedale S Maria Nuova, Reggio Emilia, Italy, ⁵Radiology, University of Bari, Bari, Italy, ⁶Bari University, Rheumatology, Bari, Italy, ⁷Children's Hospital of Pittsburgh, Pittsburgh, PA, ⁸Rheumatology, Arcispedale S.Maria Nuova, Reggio Emilia, Italy
Background/Purpose: MRI is often used to evaluate muscle inflammation in myositis. Muscle edema on fat-suppressed (short tau inversion recovery, STIR) sequences is thought to represent…
Abstract Number: 297 • 2015 ACR/ARHP Annual Meeting
How Useful Is Magnetic Resonance Imaging (MRI) in Monitoring Patients with Myositis?
Nicolo Pipitone¹, Antonella Notarnicola², Arnaldo Scardapane³, Gabriele Levrini⁴, Lucia Spaggiari⁵, Florenzo Iannone⁶, Giovanni Lapadula⁶, Giulio Zuccoli⁷ and Carlo Salvarani⁸, ¹Unità di Reumatologia, Reggio Emilia, Arcispedale Santa Maria Nuova, Bari, Italy, ²Karolinska Hospital, Rheumatology Unit, Stockholm, Sweden, ³Radiology, University of Bari, Bari, Italy, ⁴Arcispedale S Maria Nuova, Reggio Emilia, Italy, ⁵Radiology, Arcispedale S Maria Nuova, Reggio Emilia, Italy, ⁶Bari University, Rheumatology, Bari, Italy, ⁷Children's Hospital of Pittsburgh, Pittsburgh, PA, ⁸Rheumatology, Arcispedale S.Maria Nuova, Reggio Emilia, Italy
Background/Purpose: MRI is commonly used to assess muscle inflammation in myositis. Muscle edema on fat-suppressed sequences is thought to reflect active inflammation. However, it is…
Abstract Number: 304 • 2015 ACR/ARHP Annual Meeting
Abnormal Pulmonary Function Tests, Interstitial Lung Disease, and Lung Function Decline in Patients with Classic and Clinically Amyopathic Dermatomyositis
Michael George¹, Maryl Kreider², Rupal Shah², Wallace Miller Jr.³, Peter A. Merkel⁴ and Victoria Werth^5,6, ¹Department of Rheumatology, Hospital of the University of Pennsylvania, Philadelphia, PA, ²Pulmonary, Allergy & Critical Care, University of Pennsylvania, Philadelphia, PA, ³Radiology, University of Pennsylvania, Philadelphia, PA, ⁴Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁵Dermatology, Veterans Affairs Medical Center, Philadelphia, PA, ⁶Dermatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Interstitial lung disease (ILD) is common in classic dermatomyositis (DM) and clinically amyopathic dermatomyositis (CADM), in which rash is present without weakness. Previous studies…
Abstract Number: 1154 • 2015 ACR/ARHP Annual Meeting
Ajulemic Acid Is a Novel Cannabinoid That Suppresses the Secretion of TNF-α and IFN-α from the Peripheral Blood Mononuclear Cells of DM Patients In Vitro
Paul Alves^1,2, Elizabeth Robinson^1,2, Muhammad Bashir^1,3, Rui Feng⁴ and Victoria P. Werth^1,2, ¹Dermatology, Veterans Affairs Medical Center, Philadelphia, PA, ²Dermatology, University of Pennsylvania, Philadelphia, PA, ³Department of Dermatology, University of Pennsylvania, Philadelphia, PA, ⁴Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: DM is an autoimmune disease with cutaneous symptoms often accompanied by inflammatory muscle and/or lung disease. Current therapies for DM are often toxic and…
Abstract Number: 1885 • 2015 ACR/ARHP Annual Meeting
Identification and Clinical Correlations of Rare Autoantibodies in Systemic Sclerosis and Poly/Dermatomyositis Patients
Angela Ceribelli^1,2, Natasa Isailovic³, Maria De Santis⁴, Elena Generali¹, Marco Massarotti⁵, Minoru Satoh⁶ and Carlo Selmi^7,8, ¹Internal Medicine- Unit of Rheumatology and Clinical Immunology, Humanitas Clinical and Research Center, Rozzano (MI), Italy, ²BIOMETRA, University of Milan, Milan, Italy, ³Internal Medicine; Unit of Rheumatology and Clinical Immunology, Humanitas Clinical and Research Center, Rozzano (MI), Italy, ⁴Internal Medicine, Unit of Rheumatology and Clinical Immunology, Humanitas Clinical and Research Center, Rozzano (MI), Italy, ⁵Internal Medicine- Unit of Rheumatology and Clinical Immunology, Humanitas Clinical and Research Center, Rozzano (Milan), Italy, ⁶Department of Clinical Nursing, School of Health Sciences, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁷Internal Medicine- Unit of Rheumatology and Clinical Immunology, Humanitas Clinical and Research Center, Rozzano, Italy, ⁸BIOMETRA Department, University of Milan, Milan, Italy
Background/Purpose: Systemic Sclerosis (SSc), Polymyositis (PM) and Dermatomyositis (DM) are characterized by the presence of serum autoantibodies (autoAbs) which are central in the diagnosis, predicting…
Abstract Number: 2363 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Adrenocorticotropic Hormone Gel (Acthar Gel ®) in Refractory Dermatomyositis or Polymyositis
Rohit Aggarwal¹, Galina Marder², Priyadarshini Loganathan³, Diane Koontz⁴, Preeya Nandkumar⁵, Zengbiao Qi⁶ and Chester V. Oddis⁷, ¹Rheumtology, University of Pittsburgh Medical Center, Pittsburgh, PA, ²Medicine, North Shore Long Island Health System, Great Neck, NY, ³University of Pittsburgh Medical Center, Pittsburgh, PA, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵North Shore Long Island Health System, Great Neck, NY, ⁶Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁷Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Adrenocorticotropic hormone (ACTH) gel (repository corticotropin injection) is a long-acting full sequence ACTH that may include other pro-opiomelanocortin peptides thought to have anti-inflammatory and…
Abstract Number: 2369 • 2015 ACR/ARHP Annual Meeting
Dermatomyositis Associated with Anti-Melanoma Differentiation-Associated Gene 5 Antibodies: A Longitudinal Analysis
Matthew Lewis¹, Shufeng Li¹, Lorinda Chung² and David Fiorentino¹, ¹Dermatology, Stanford University, Stanford, CA, ²Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA
Background/Purpose: Dermatomyositis (DM) patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibodies are at increased risk of developing interstitial lung disease (ILD). The natural history of…
Abstract Number: 2373 • 2015 ACR/ARHP Annual Meeting
Frequency of Antinuclear (ANA), Myositis-Specific (MSA) and Myositis-Associated Antibodies (MAA) in Patients with Idiopathic Inflammatory Myopathies (IIM) from Mexico, Central and South America Centers: Data from the Panlar Myositis Study Group.
Yelitza Gonzalez-Bello^1,2, Daniel Garcia-Cerda³, Gabriel Medrano-Ramírez⁴, José E. Navarro-Zarza⁵, Lilia Andrade-Ortega⁶, Marco Maradiaga-Ceceña⁷, Alicia Cardenas-Anaya⁸, Arnulfo H. Nava-Zavala^3,9, Gerardo Orozco-Barocio⁸, Armando Rojo-Mejia¹⁰, Esthela Loyo¹¹, Paola Gottschalk¹¹, Graciela Gómez¹², Marvin J. Fritzler¹³ and Ignacio Garcia-De La Torre⁸, ¹Immunology and Rheumatlogy, Universidad de Guadalajara, Zapopan, Jalisco, Mexico, ²Immunology and Rheumatology, Hospital General de Occidente, Secretaria de Salud Jalisco, Guadalajara, Jalisco, Mexico, ³Immunology and Rheumatology, Hospital General de Occidente, Secretaria de Salud Jalisco, Zapopan, Jal., Mexico, ⁴Rheumatology, Hospital General de Mexico, Secretaria de Salud, Mexico City, Mexico, ⁵Medicine, Hospital General Raymundo Abarca Alarcón, Chilpancingo, Mexico, ⁶Rheumatology, Centro Medico Nacional 20 de Noviembre, ISSSTE, Mexico City, Mexico, ⁷Rheumatology, Hospital General de Culiacan de la Secretaría de Salud, Culiacan, Sin., Mexico, ⁸Immunology and Rheumatology, Hospital General de Occidente, Secretaria de Salud Jalisco, Zapopan, Jalisco, Mexico, ⁹UMAE, Hospital de Especialidades Centro Médico Nacional de Occidente, IMSS, Guadalajara, Jalisco, Mexico, ¹⁰Rheumatology, Clinica San Pablo, Lima, Peru, ¹¹Rheumatology, Hospital Regional Universitario, Santiago, Dominican Republic, ¹²Rheumatology, Instituto de Investigaciones Medicas Alfredo Lanari, Buenos Aires, Argentina, ¹³Medicine, University of Calgary, Calgary, AB, Canada
Background/Purpose: Dermatomyositis (DM) and polymyositis (PM) are forms of IIM that involve skeletal muscle as well as many other organs. As in other systemic rheumatic…
Abstract Number: 2376 • 2015 ACR/ARHP Annual Meeting
Clinical Features in Dermatomyositis Patients with Novel Autoantibody to Small Ubiquitin-like Modifier Activating Enzymes (Anti-SAE Antibody) and Relationship to Interstitial Lung Disease: A Systematic Review of 29 Cases
Sirada Panupattanapong¹, Jessica Sun² and Kevin Baszis¹, ¹Pediatrics, Division of Rheumatology, Washington University School of Medicine, St. Louis Children's Hospital, St. Louis, MO, ²Pediatric, Division of Rheumatology, Washington University School of Medicine, St. Louis Children's Hospital, St. Louis, MO
Background/Purpose: Anti-SAE antibody is a novel myositis-specific antibody first described in 2007. SAE is an enzyme that facilitates sumoylation, leading to the formation of stable…
Abstract Number: 2380 • 2015 ACR/ARHP Annual Meeting
Jo-1 Positive Myositis Patients Tend to Have More Severe Muscle and Lung Involvement Than PM-Scl Positive Patients
Julie J. Paik¹, Arash Lahoutiharahdashti², Andrew Mammen³ and Lisa Christopher-Stine⁴, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Center Tower Ste 5300, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Ste 4100 Rm 409, Johns Hopkins University School of Medicine, Baltimore, MD
Jo-1 positive myositis patients tend to have more severe muscle and lung involvement than PM-Scl positive patients Background/Purpose: Jo-1 and PM-Scl positive myositis patients share…
Abstract Number: 2421 • 2015 ACR/ARHP Annual Meeting
Experience with Adalimumab for Treatment of 568 Juvenile Idiopathic Arthritis Patients in the German JIA Biologics Register
Gerd Horneff¹, Gerd Ganser², Ivan Foeldvari³, Johannes Peter Haas⁴, Toni Hospach⁵, Ralf Trauzeddel⁶, Frank Weller-Heinemann⁷, J B. Kuemmerle-Deschner⁸, Angelika Thon⁹ and BIKER study group, ¹Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ²Pediatric Rheumatology, Sankt Josef Stift, Sendenhorst, Germany, ³Rheumatology, Scleroderma, Hamburg, Germany, ⁴German Centre for Rheumatology in Children and Young People, Garmisch-Partenkirchen, Germany, ⁵Pediatrics, Olgahospital, Klinikum Stuttgart, Stuttgard, Germany, ⁶HELIOS Klinikum Berlin-Buch Klinik fuer Kinder- und Jugendmedizin, Berlin, Germany, ⁷PRINTO, Genoa, Italy, ⁸Pediatrics, University Hospital Tuebingen, Tuebingen, Germany, ⁹Kinderklinik der Medizinischen Hochschule Hannover, Hannover, Germany
Background/Purpose: Adalimumab (ADA) has become a valuable option for treatment of juvenile idiopathic arthritis (JIA), which significantly improves the outcome of patients. The aim of…
Abstract Number: 912 • 2014 ACR/ARHP Annual Meeting
A Consensus Hybrid Definition Using a Conjoint Analysis Is the Proposed As Response Criteria for Minimal and Moderate Improvement for Adult Polymyositis and Dermatomyositis Clincal Trials
Rohit Aggarwal¹, Lisa G. Rider², Nicolino Ruperto³, Nastaran Bayat², Brian Erman⁴, Brian M. Feldman⁵, Adam M. Huber⁶, Chester V. Oddis⁷, Ingrid E. Lundberg⁸, Anthony A. Amato, MD^9,10, Robert G. Cooper, MD, FRCP¹¹, Hector Chinoy¹², Maryam Dastmalchi¹³, David Fiorentino¹⁴, David Isenberg¹⁵, James D. Katz¹⁶, Andrew L. Mammen¹⁷, Marianne de Visser¹⁸, Steven R. Ytterberg¹⁹, Katalin Danko²⁰, Luca Villa²¹, Mariangela Rinaldi²¹, Howard Rockette²², Peter A. Lachenbruch², Frederick W. Miller² and Jiri Vencovsky, MD, DSc²³, ¹Medicine, University of Pittsburgh, Pittsburgh, PA, ²Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ³Pediatria II,, Istituto Giannina Gaslini, Genoa, Italy, ⁴Social and Scientific Systems, Inc., Durham, NC, ⁵Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁶IWK Health Centre, Halifax, NS, Canada, ⁷Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁸Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ⁹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ¹⁰Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ¹¹MRC/ARUK Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom, ¹²Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ¹³Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, ¹⁴Dermatology, Stanford University, Redwood City, CA, ¹⁵Centre for Rheumatology Research, Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, ¹⁶NIAMS, NIH, Bethesda, MD, ¹⁷Neurology and Medicine, Johns Hopkins University, Baltimore, MD, ¹⁸Department of Neurology, Academic Medical Centre, Amsterdam, Netherlands, ¹⁹Rheumatology Division, Mayo Clinic, Rochester, MN, ²⁰Institute of Rheumatology, University of Debrecen, Hungary, Debrecen, Hungary, ²¹Pediatria II, Reumatologia, PRINTO, IRCCS Istituto G. Gaslini, Genova, Italy, ²²University of Pittsburgh, Pittsburgh, PA, ²³Institute of Rheumatology, Charles University, Prague, Czech Republic
Background/Purpose: To develop consensus on definitions of improvement (DOIs) for minimal and moderate improvement (and draft preliminary criteria for major improvement) in adult dermatomyositis (DM)…
Abstract Number: 2539 • 2014 ACR/ARHP Annual Meeting
Antibodies to Human Interferon-Inducible Protein-16 Are Present in Primary Sjögren’s Syndrome and Systemic Lupus, but Are Rare in Dermatomyositis
Alan N. Baer¹, Michelle Petri², David Fiorentino³, Tao Wang⁴, Jungsan Sohn⁴, Antony Rosen¹ and Livia Casciola-Rosen⁵, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, ⁴Biophysics and Biophysical Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Center Tower Ste 5300, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Interferon inducible protein-16 (IFI16) is an intracellular DNA receptor involved in innate immunity. We evaluated the frequency and clinical significance of anti-IFI16 antibodies in…
Abstract Number: 2211 • 2014 ACR/ARHP Annual Meeting
Epidemiologic and Clinical Features of Patients with Adult and Juvenile Dermatomyositis, Polymyositis and Inclusion Body Myositis from Myovision, a National Myositis Patient Registry
Abdullah Faiq¹, Payam Noroozi Farhadi¹, Nastaran Bayat¹, Mikaela Chase¹, Anna Jansen¹, Karen Malley², Jesse Wilkerson³, Kathryn Rose⁴, Caroll Co⁴, Lukasz Itert⁵, Anne Johnson⁶, Richard Morris⁴, Christine Parks⁷, Edward H. Giannini⁸, Hermine I. Brunner⁸, Frederick W. Miller¹, Bob Goldberg⁹ and Lisa G. Rider¹, ¹Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ²Malley Research Programming, Inc, Bethesda, MD, ³Social and Scientific Systems, Inc., Research Triangle Park, NC, ⁴Social and Scientific Systems, Inc., Durham, NC, ⁵Division of Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁷Epidemiology Branch, NIEHS, NIH, Research Triangle Park, NC, ⁸Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁹The Myositis Association, Alexandria, VA
Background/Purpose: The myositis syndromes are rare systemic autoimmune diseases, little is known about their epidemiology. We describe the demographics and comorbidities of patients in a…
Abstract Number: 2214 • 2014 ACR/ARHP Annual Meeting
Power Doppler Ultrasonography for Detection of Abnormal Fascial Vascularity: A Potential Early Diagnostic Tool in Fasciitis of Dermatomyositis
Ken Yoshida¹, Makiko Nishioka², Satoshi Matsushima², Kensuke Joh³, Yosuke Oto¹, Yoshiga Masayuki¹, Kazuhiro Otani¹, Haruyash Ito¹, Kenichiro Hirai¹, Kazuhiro Furuya¹, Taro Ukichi¹, Kentaro Noda¹, Isamu Kingetsu¹ and Daitaro Kurosaka¹, ¹Internal Medicine, Jikei University School of Medicine, Tokyo, Japan, ²Rheumatology, Jikei University School of Medicine, Tokyo, Japan, ³Pathology, Tohoku University Graduate School of Medicine, Sendai, Japan
Background/Purpose We have previously demonstrated that fasciitis is a common lesion of dermatomyositis (DM) detectable early after disease onset by en bloc biopsy combined with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].